• Superiority of thrombectomy within 8 hours of anterior circulation large vessel occlusion over medical therapy

    REVASCAT was a multicenter randomized controlled trial enrolling patients within 8 hours of symptom onset and confirmed anterior circulation, large vessel occlusion.  Patients were randomized to medical therapy versus medical therapy plus thrombectomy with the Solitaire FR Stent Retriever device. The trial was halted after enrollment of 206 patients due to a loss of equipoise in light of other recently positive thrombectomy trials.  At 90 days, functional independence defined as mRS 0-2 was achieved in 43.7% of thrombectomy patients versus 28.2% of medical therapy patients (OR 2.1 with 95% CI 1.1-4.0).  Symptomatic hemorrhage rates were equal in both groups at 1.9%.Given the increased time horizon in this trial, not all patients received IV alteplase.  Unlike other recent trials, patients with tandem occlusions were permitted in the trial and a more stringent ASPECTS criteria score of 7 was required (quantifying volume of completed pre-procedural infarct).REVASCAT adds to the recent positive evidence regarding thrombectomy for confirmed large vessel occlusion, and suggests clinical benefit in patients with a longer time to presentation and independent of IV tPA administration



    New England Journal of Medecine

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy